Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAI of FOLFOX vs Sorafenib in TACE-Resistant HCC
NCT02220088Phase 3Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2014
- Primary completion
- Jul 2018
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression Free Survival at 1 year. Started Dec 2014; status: terminated.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02220088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220088.